
Search Clinical Trials
Sponsor Condition of Interest |
---|
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced,1
Takeda
Colorectal Cancer
High blood pressure (hypertension) is a known side effect of the treatment with
fruquintinib. Current research does not provide a clear answer whether minority groups
such as Black/African American and/or Hispanic/Latino with refractory metastatic
colorectal cancer (mCRC) have a bigger risk of high1 expand
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants. Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion. Type: Interventional Start Date: Jan 2025 |
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
Celldex Therapeutics
Chronic Spontaneous Urticaria
The purpose of this study is to establish the efficacy, safety and tolerability of
barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately
controlled by non-sedating second generation H1-antihistamines in comparison to placebo. expand
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo. Type: Interventional Start Date: Jul 2024 |
Early Onset Colorectal Cancer Detection
City of Hope Medical Center
Colorectal Cancer
Colorectal Neoplasms
Colorectal Adenocarcinoma
Colorectal Cancer Stage I
Colorectal Cancer Stage IV
Colorectal cancer (CRC) once predominantly affected older individuals, but in recent
years has witnessed a progressive increase in incidence among young adults. Once rare,
early-onset colorectal cancer (EOCRC, that is, a CRC diagnosed before the age of 50) now
constitutes 10-15% of all newly diagno1 expand
Colorectal cancer (CRC) once predominantly affected older individuals, but in recent years has witnessed a progressive increase in incidence among young adults. Once rare, early-onset colorectal cancer (EOCRC, that is, a CRC diagnosed before the age of 50) now constitutes 10-15% of all newly diagnosed CRC cases and it stands as the first cause of cancer-related death in young men and the second for young women. This study aims to detect EOCRC with a non-invasive test, using a blood-based molecular assay based on microRNA (ribonucleic acid) Type: Observational Start Date: Apr 2023 |
The Impact of Expressive Emotional Writing on Facilitating Grief Resolution in Adults With Spinal C1
University of Alabama at Birmingham
Spinal Cord Injuries
Transverse Myelitis
The aim of this study is to evaluate the therapeutic benefits of a 10-week online
coach-guided EEWP on psychosocial health among adults with SCI. expand
The aim of this study is to evaluate the therapeutic benefits of a 10-week online coach-guided EEWP on psychosocial health among adults with SCI. Type: Interventional Start Date: May 2024 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progr1
Bristol-Myers Squibb
Progressive Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of
BMS-986278 in Participants with Progressive Pulmonary Fibrosis. expand
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis. Type: Interventional Start Date: Oct 2023 |
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary1
Hoffmann-La Roche
Primary IgA Nephropathy
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of
sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants
with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease
despite optimized supportive care. expand
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care. Type: Interventional Start Date: Aug 2023 |
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satra1
Hoffmann-La Roche
NMDAR Autoimmune Encephalitis
LGI1 Autoimmune Encephalitis
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab
in participants with NMDAR and LGI1 encephalitis. expand
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis. Type: Interventional Start Date: Sep 2022 |
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific1
American Society of Clinical Oncology
Lymphoma, Non-Hodgkin
Multiple Myeloma
Advanced Solid Tumors
The purpose of the study is to learn from the real world practice of prescribing targeted
therapies to patients with advanced cancer whose tumor harbors a genomic variant known to
be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include1 expand
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). ******************************************************************** Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. ******************************************************************** Type: Interventional Start Date: Mar 2016 |
A Study of Doxycycline to Treat Chlamydial Infection
National Institute of Allergy and Infectious Diseases (NIAID)
Chlamydial Infection
This is a Phase 4 blinded, randomized, active-controlled, non-inferiority trial. Final
evaluable population will include a minimum 596 individuals: 298 women with confirmed
urogenital chlamydia (CT) and 298 men with confirmed rectal chlamydia (CT). Approximately
664 participants will be enrolled to1 expand
This is a Phase 4 blinded, randomized, active-controlled, non-inferiority trial. Final evaluable population will include a minimum 596 individuals: 298 women with confirmed urogenital chlamydia (CT) and 298 men with confirmed rectal chlamydia (CT). Approximately 664 participants will be enrolled to achieve a minimum 596 participants who contribute primary outcome data. Randomization will be stratified by study site and sex: 332 women and 332 men. Participants will be randomized 1:1 to a 3-day regimen of doxycycline or a 7-day regimen of doxycycline. The study blind will be maintained by providing 7 days of identical pre-filled blister packs, one with 3 days of active treatment and 4 days of placebo, and the other with 7 days of active treatment. Participants will be asked to return 28 days after randomization (at day 29), at which time they will be re-tested for chlamydia (CT) using a laboratory-based chlamydia (CT) nucleic acid amplification test (NAAT). Type: Interventional Start Date: Jan 2024 |
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed D1
National Human Genome Research Institute (NHGRI)
Genetic Disease
Without an explanation for severe and sometimes life-threatening symptoms, patients and
their families are left in a state of unknown. Many individuals find themselves being
passed from physician to physician, undergoing countless and often repetitive tests in
the hopes of finding answers and insig1 expand
Without an explanation for severe and sometimes life-threatening symptoms, patients and their families are left in a state of unknown. Many individuals find themselves being passed from physician to physician, undergoing countless and often repetitive tests in the hopes of finding answers and insight about what the future may hold. This long and arduous journey to find a diagnosis does not end for many patients- the Office of Rare Diseases Research (ORDR) notes that 6% of individuals seeking their assistance have an undiagnosed disorder. In 2008, the National Institutes of Health (NIH) Undiagnosed Diseases Program (UDP) was established with the goal of providing care and answers for these individuals with mysterious conditions who have long eluded diagnosis. The NIH UDP is a joint venture of the NIH ORDR, the National Human Genome Research Institute Intramural Research Program (NHGRI-IRP), and the NIH Clinical Research Center (CRC) (1-3). The goals of the NIH UDP are to: (1) provide answers for patients with undiagnosed diseases; (2) generate new knowledge about disease mechanisms; (3) assess the application of new approaches to phenotyping and the use of genomic technologies; and (4) identify potential therapeutic targets, if possible. To date, the UDP has evaluated 3300 medical records and admitted 750 individuals with rare and undiagnosed conditions to the NIH Clinical Center. The NIH UDP has identified more than 70 rare disease diagnoses and several new conditions. The success of the NIH UDP prompted the NIH Common Fund to support the establishment of a network of medical research centers, the Undiagnosed Diseases Network (UDN), for fiscal years 2013-2020. The clinical sites will perform extensive phenotyping, genetic analyses, and functional studies of potential disease-causing variants. The testing performed on patients involves medically indicated studies intended to help reach a diagnosis, as well as research investigations that include a skin biopsy, blood draws, and DNA analysis. In addition, the UDN will further the goals of the UDP by permitting the sharing of personally identifiable phenotypic and genotypic information within the network. By sharing participant information and encouraging collaboration, the UDN hopes to improve the understanding of rare conditions and advance the diagnostic process and care for individuals with undiagnosed diseases. Type: Observational Start Date: Sep 2015 |
T1D Pregnancy & Me
Jaeb Center for Health Research
Diabetes Mellitus, Type 1
Pregnancy in Diabetics
Pregnancy, High-Risk
Insulin Dependent Diabetes
T1D Pregnancy & Me will partner with pregnant participants living with type 1 diabetes
(T1D) in the United States to collect real-world data on management of T1D in pregnancy.
This is a remote study where participants can complete online surveys and share device
data (continuous glucose monitor (CG1 expand
T1D Pregnancy & Me will partner with pregnant participants living with type 1 diabetes (T1D) in the United States to collect real-world data on management of T1D in pregnancy. This is a remote study where participants can complete online surveys and share device data (continuous glucose monitor (CGM) data and insulin data). Through the collection of CGM, insulin, and pregnancy outcome data, the study will provide important information to understand how diabetes is being managed during pregnancy. These data will provide much needed evidence to guide modern management of diabetes during pregnancy with a goal of improving care and outcomes. Type: Observational Start Date: Apr 2025 |
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
University of Alabama at Birmingham
Stroke
Transient Ischemic Attack (TIA)
The purpose of this research study is to explore whether genetic testing can offer a
personalized and timely approach to assist physicians in making more informed medication
decisions for stroke or high-risk transient ischemic attack (TIA) patients during their
hospital stay. expand
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay. Type: Interventional Start Date: Apr 2025 |
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Dis1
University of Rochester
Sickle Cell Disease (SCD)
The WeDecide study is a large observational study comparing the long-term effects of
matched related donor hematopoietic stem cell transplantation (MRD HCT) and
non-transplant disease-modifying therapies (NT-DMT) for pediatric patients with sickle
cell disease (SCD). The study aims to assess health1 expand
The WeDecide study is a large observational study comparing the long-term effects of matched related donor hematopoietic stem cell transplantation (MRD HCT) and non-transplant disease-modifying therapies (NT-DMT) for pediatric patients with sickle cell disease (SCD). The study aims to assess health-related quality of life (HRQoL), cognitive function, risks, and benefits of both treatments, including survival rates, chronic complications, and organ damage prevention. With 160 children in the MRD HCT group and 320 in the NT-DMT group, aged 3-20.9 years, the study will follow participants for three years, examining factors like disease severity, treatment history, and social determinants of health. By providing a comprehensive comparison, the study seeks to inform clinical decisions and improve understanding of SCD treatment outcomes, ultimately supporting families and healthcare providers in choosing the best treatment options. Type: Observational Start Date: Jun 2024 |
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
University of Alabama at Birmingham
Brain Metastases
Radiosurgery is the use of a focal high dose of radiation therapy to ablate or kill a
tumor. This trial will enroll patients with brain metastases 4 cm or less in greatest
diameter and will compare 0mm margin to a 2mm margin for treatment. expand
Radiosurgery is the use of a focal high dose of radiation therapy to ablate or kill a tumor. This trial will enroll patients with brain metastases 4 cm or less in greatest diameter and will compare 0mm margin to a 2mm margin for treatment. Type: Interventional Start Date: Apr 2025 |
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofi1
Healx Limited
Neurofibromatosis Type 1
The trial will be an open label, single arm, phase 2 study in 20 participants. The study
will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years
of age or older with progressive and/or symptomatic PN. expand
The trial will be an open label, single arm, phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN. Type: Interventional Start Date: Jan 2025 |
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Partic1
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene
Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma. expand
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma. Type: Interventional Start Date: Mar 2024 |
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
Duke University
Atherosclerotic Cardiovascular Disease
VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an
innovative therapy with the potential to help bridge care gaps in historically
understudied and undertreated populations by leveraging electronic health records (EHR)
in multiple US Healthcare Systems (HCS) to1 expand
VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthcare Systems (HCS) to systematically identify those at high risk for and already diagnosed with ASCVD for more expeditious achievement of LDL-C targets. Type: Interventional Start Date: Dec 2024 |
Shockwave Lithoplasty Compared to Cutting Balloon Treatment in Calcified Coronary Disease - A Rando1
Baim Institute for Clinical Research
Treatment in Calcified Coronary Disease
The Short-Cut trial is a prospective, investigator-initiated, multicenter, randomized
controlled trial that is designed to compare the efficacy of cutting balloon angioplasty
vs. intravascular lithotripsy prior to drug-eluting stent implantation in patients with
moderate to severely calcified coron1 expand
The Short-Cut trial is a prospective, investigator-initiated, multicenter, randomized controlled trial that is designed to compare the efficacy of cutting balloon angioplasty vs. intravascular lithotripsy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries. Type: Interventional Start Date: Dec 2023 |
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and i1
Genentech, Inc.
Locally Advanced Solid Tumors
Recurrent Solid Tumors
Metastatic Solid Tumors
This is a first-in-human Phase I, open-label, dose-escalation and expansion study
designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity,
pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and
in combination with atezolizumab in participants1 expand
This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion. Type: Interventional Start Date: Nov 2023 |
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
Shape Memory Medical, Inc.
Aortic Aneurysm, Abdominal
To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the
percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as
an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial
subjects considered candidates for elect1 expand
To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR. Type: Interventional Start Date: Apr 2024 |
Investigating Dynamic Interactions in Distributed Cognitive Control Networks
University of Alabama at Birmingham
Cognitive Impairment
Dementia
ADD
Depression
The purpose of this study is to investigate the brain activity associated with cognitive
tasks (thinking, reasoning, remembering) in order to understand how the brain works
during certain tasks and to improve treatment for diseases like dementia and attention
deficit disorders. Cognitive (thinking)1 expand
The purpose of this study is to investigate the brain activity associated with cognitive tasks (thinking, reasoning, remembering) in order to understand how the brain works during certain tasks and to improve treatment for diseases like dementia and attention deficit disorders. Cognitive (thinking) impairment may include poor memory function, poor attention span, or psychiatric disorders (ex: ADD, depression). The investigators are interested in the brain activity related to these issues, and want to investigate changes in brain activity while we record activity from specific areas of the brain. These recordings are in addition to clinical (routine or standard of care) recordings being performed to monitor for seizures and do not impact the clinical care. Type: Observational Start Date: Mar 2023 |
A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin1
Pfizer
Lupus Erythematosus, Systemic
Lupus Erythematosus, Cutaneous
The purpose of this study is to learn about the effects, safety and how PF-06823859 is
processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus
erythematosus (SLE) showing some skin symptoms.
This study is seeking for participants who:
- are adults of 18 years of age or o1 expand
The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms. This study is seeking for participants who: - are adults of 18 years of age or older. - are confirmed to have CLE or SLE with involvement of the skin. - have a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity (CLASI-A) score of at least 8. About 48 participants will be selected to receive active study medicine (PF-06823859) or placebo (an infusion without drug). About 32 are grouped to receive the active study medicine and 16 are to receive placebo. They will be receiving the treatments by intravenous infusion (injected directly into the veins). At week 16 all participants receiving the active study drug since day 1 and participants who have received placebo since day 1 and are not responding clinically will receive active study medication. Patients who have received placebo since Day 1 and who have had a clinical response will continue to receive placebo till week 40. All participants will have last follow-up visit at Week 60. The study will compare participants receiving PF-06823859 to participants who receive placebo. This will help us see if PF-06823859 is safe and effective to treat CLE or SLE with skin symptoms and improve participant's CLASI-A score. Participants will take part in this study for about 65 weeks. This includes up to a 5-week selection period, a 12-week Q4Wk treatment period, a 36-week Q8Wk treatment period, and a 12-week follow-up period. Type: Interventional Start Date: Jul 2023 |
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary1
Genentech, Inc.
Idiopathic Pulmonary Fibrosis
Systemic Sclerosis With Lung Involvement
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with
placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in
participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Participants who complete 52-weeks of1 expand
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has completed enrollment and has been closed for further enrollment. Cohort 2 is enrolling participants. Type: Interventional Start Date: May 2023 |
Executive Functioning Training Study
University of Alabama at Birmingham
Aging
Cognitive Function Abnormal
Cognitive Performance
Cognitive Training
Older Adults
Cognitive aging in people with HIV (PWH) is of increasing concern for several reasons: 1)
between 52%-59% of PWH experience cognitive impairment known as HIV-Associated
Neurocognitive Disorder (HAND) which impacts everyday functioning and quality of life; 2)
HAND increases in severity and prevalenc1 expand
Cognitive aging in people with HIV (PWH) is of increasing concern for several reasons: 1) between 52%-59% of PWH experience cognitive impairment known as HIV-Associated Neurocognitive Disorder (HAND) which impacts everyday functioning and quality of life; 2) HAND increases in severity and prevalence with age; and 3) 70% of PWH in the United States will be 50 and older by 2030. Fortunately, cognitive training programs can individually target specific cognitive impairments in PWH and possibly reduce the severity and prevalence of HAND and improve everyday functioning and quality of life. This approach is based around the underlying concept of intra-individual variability as controlled through higher level allocation of cognitive resources, known as executive functioning. This feasibility study will use a two-group pre-post experimental design of adults with HAND including: 1) a 20-hours of Executive Functioning Training group (enroll 60, n=48 with attrition), and 2) a no-contact control (enroll 60, n=48 with attrition). Aim 1 - Feasibility: To determine feasibility and acceptability of the intervention (i.e., attrition, feedback). Exploratory Aim 1 - Cognition: Compare adults who receive Executive Functioning Training to those who receive no training to determine whether they improve in global cognitive ability and overall cognitive IIV. This high impact study is innovative in the following ways: 1) This is the first study aimed to reduce cognitive IIV in PWH. 2) This is the first study to use IIV as a guide to target solely executive functioning training to improve global cognitive ability, which may reduce the severity and prevalence of HAND. 3) Over the last decade, the epicenter of HIV has emerged in the Deep South where this study will occur. Most participants in this study will be older PWH who identify as lower social economic status (SES) and/or African Americans and experience HAND symptoms. Type: Interventional Start Date: Jun 2023 |
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
Gynecologic Cancer
Carcinoma
Uterine Cancer
Endometrial Cancer
Immunotherapy has gained a significant amount of attention recently, but its efficacy as
a single agent in gynecological cancers has been disappointing. Pre-clinical evidence
supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors
with immunotherapy. VEGF inhibitors1 expand
Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing. Pre-clinical evidence supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with immunotherapy. VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs) and VEGF has been shown to affect the functional maturation of dendritic cells; therefore, VEGF inhibitors could improve the function of antigen presentation. In this study, Cabozantinib (VEGF inhibitor) and Dostarlimab (immunotherapeutic drug) will be admnistered as a combination to patients with recurrent gynecologic carcinosarcoma. Type: Interventional Start Date: Aug 2023 |
- Previous
- Next